Happy memory of the 10th APRIS annual meeting in Seoul. Great opportunity to present and discuss our research on diabetic choroidopathy and clinical experiences with brolucizumab for nAMD!
#APRIS2023 #choroidopathy #brolucizumab

We provide Brolucizumab biosimilar for research use!

Brolucizumab is a humanized single-chain antibody fragment that was designed to attach to and block a substance called vascular endothelial growth factor A.

ScienceMagazine: Harnessing structural and immunological techniques, scientists identify immunogenic factors leading to immune complexes that may explain why #brolucizumab can elicit rare cases of retinal side effects in patients. Science Translational Medicine …

This study in #GraefesArchiveforClinicalandExperimentalOphthalmology evaluates flare levels after intravitreal injection of brolucizumab for diabetic macular edema link.springer.com/article/10.100…

Discover a comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration #GraefesArchiveforClinicalandExperimentalOphthalmology
link.springer.com/article/10.100…

Da comienzo la mesa de #retina médica en el #congreso Sociedad Española de Retina y Vítreo con el Dr.Escobar y #brolucizumab en #edemamaculardiabetico

Adverse events related to intraocular inflammation occurred in 53/505 (10.5%) patients on brolucizumab in the OCTOPUS Incidence of and SWIFT intraocular inflammation prospective trials, mostly during loading phase with retinal involvement was 3.4%. ow.ly/mmjY50P53tt

Brolucizumab, a monoclonal antibody for macular degeneration, caused rare retinal side effects in 2 new studies due to immune system interactions.

#health #twitter #TrendingNow #NowStreaming #medtwitter

New Ophthalmology Retina is online now! Featuring articles on retinal detachment repair & laser prophylaxis, management of intraocular inflammation after brolucizumab treatment, technique for scleral fixation of an intraocular telescopic device, & more ow.ly/UcYb50PSnI2

INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN
A Multicenter Age-Related Macular Degeneration Study
Inoda, Satoru MD, PhD; et. al.
Retina 44(4):p 714-722, April 2024
journals.lww.com/retinajournal/…
#retina

Japanese investigators may have found of way of predicting which patients will develop intraocular inflammation following brolucizumab injections (Beovue, Novartis) administered to treat neovascular age-related macular degeneration (nAMD)

Read More: ow.ly/E55Z50Qhm8y

At 12 months, brolucizumab tx prolonged interval between anti-VEGF injections for most treatment-experienced eyes. Post hoc data has shown incidences of intraocular inflammation of 4.6%, retinal vasculitis of 3.3%, & retinal vascular occlusion of 2.1% ow.ly/zXXp50NXPJ4

Post-marketing setting analysis reveals posterior segment inflammatory changes that may occur in brolucizumab-treated patients and highlights the potential value of wide-field retinal imaging and angiography to detect these adverse events ow.ly/NlJ050P68sK

Study of patients w/wet AMD switching to brolucizumab showed that shorter pre-switch injection interval allowed interval extension. Historically, intraocular inflammation was 4.6% and was 3.3% for retinal vasculitis & 2.1% for retinal vascular occlusion. ow.ly/Nqlk50NwYSZ

Ready for summer fun? 🌞 Check out our new Retina podcast - perfect for tuning into while on vacation! Hear from Dr. Kenneth Phan & learn about RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. #RetinaPodcast #retina

La Dra. Cilveti, comparte los primeros resultados del estudio de práctica clínica habitual con #Beovu #Brolucizumab en #DMArte . Su eficacia y sus efectos adversos.

Dr Satoru Inoda's paper evaluating intra ocular inflammation after brolucizumab at 14 Japanese centres has been published.

Un placer compartir cartel con mis compañeros Pilar Calvo MD PhD y Oscar RuizMoreno para mostrar nuestra experiencia con #brolucizumab #beovu en #DMAE en @oftalmologiahcu del Hospital Clínico de Zaragoza #DMArTE Novartis Sociedad Española de Retina y Vítreo Colegio de Médicos de Zaragoza Sociedad Española de Oftalmología Universidad Zaragoza

1/3 ¿Tratamiento del #EdemaMacularDiabético ( #EMD ) son todos los fármacos intravítreos #anti -VEGF iguales?

Ha sido publicada una #RevisiónSistemáticaCochrane en Pacientes con #EMD tratados con #Aflibercept , #Bevacizumab , #Brolucizumab y #Ranibizumab con seguimiento a 24 meses

Ophthopedia Update: INTRAOCULAR INFLAMMATION INCIDENCE AFTER INTRAVITREAL BROLUCIZUMAB INJECTION FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION #Ophthotwitter #Ophthalmology #Retina dlvr.it/SwKmyS